Bangkok Genomics Innovation Balance Sheet Health
Financial Health criteria checks 6/6
Bangkok Genomics Innovation has a total shareholder equity of THB235.8M and total debt of THB0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are THB293.0M and THB57.2M respectively. Bangkok Genomics Innovation's EBIT is THB33.6M making its interest coverage ratio 20.5. It has cash and short-term investments of THB165.9M.
Key information
0%
Debt to equity ratio
฿0
Debt
Interest coverage ratio | 20.5x |
Cash | ฿165.90m |
Equity | ฿235.82m |
Total liabilities | ฿57.20m |
Total assets | ฿293.02m |
Recent financial health updates
No updates
Recent updates
No updates
Financial Position Analysis
Short Term Liabilities: BKGI's short term assets (THB212.1M) exceed its short term liabilities (THB35.6M).
Long Term Liabilities: BKGI's short term assets (THB212.1M) exceed its long term liabilities (THB21.6M).
Debt to Equity History and Analysis
Debt Level: BKGI is debt free.
Reducing Debt: BKGI has not had any debt for past 5 years.
Debt Coverage: BKGI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BKGI has no debt, therefore coverage of interest payments is not a concern.